drugset
drugset / Trial / NCT00517348

Study Evaluating IMA-026 in Healthy Subjects

NCT00517348 ↗

Phase 1 Completed 50 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
RandomizedParallel-groupTriple-blindTreatment

Summary

To assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of IMA-026 administered subcutaneously (SC) or intravenously (IV) in healthy adults.

Timeline

Start
2007-09
Primary completion
2008-07
Completion
2008-07

Drugs

EvaluationDrugModalityDoseRoute
Subject IMA-026 Unknown 0.3 mg/kg Subcutaneous
Subject IMA-026 Unknown 1 mg/kg Subcutaneous
Subject IMA-026 Unknown 2 mg/kg Subcutaneous
Subject IMA-026 Unknown 3 mg/kg Subcutaneous
Subject IMA-026 Unknown 4 mg/kg Subcutaneous

Indications

No indication recorded.